Vielight Red Light Therapy Review 2026: Neuro Gamma, Alpha, Duo & Vagus Prices

Quick Answer: Vielight’s current lineup runs from the $349 MIP 633-810 nasal device to the $5,000 Neuro Pro 2, with the brain-targeted Neuro Gamma 4 and Neuro Alpha 4 at $1,799 each and the combined Neuro Duo 4 at $2,399, per Vielight’s own store. Vielight’s Neuro Gamma line bets on 40Hz brain-wave gamma entrainment for cognition — the same underlying science behind Cognito Therapeutics’ Spectris AD, which holds FDA Breakthrough Device Designation and completed a 670-patient sham-controlled pivotal trial in 2026 before seeking clearance. Vielight’s devices, by contrast, are sold today as general wellness products under a trial the company announced back in 2019 that hasn’t yet led to a disease-specific FDA clearance.

Vielight already shows up on this site as our top pick in several nasal and condition guides — the X-Plus 4 leads our best nasal red light therapy guide and gets recommended for sinus, allergies, and off-label tinnitus use — but the brand has never had its own dedicated review covering its full lineup, including the brain-targeted Neuro devices those guides don’t mention. This one prices the whole catalog direct from Vielight’s store and looks closely at the regulatory story behind its highest-priced, most science-forward product line.

Vielight’s lineup by the numbers

• Nine devices across two product families, per Vielight’s own store: four brain-targeted “Neuro” devices ($1,799-$5,000), a vagus-nerve device ($699), and four nasal/thymus “MIP” devices including the X-Plus 4 ($349-$499).
• Neuro Gamma 4 and Neuro Alpha 4 are both $1,799 and use identical 810nm near-infrared hardware — the only difference is the pulse frequency the driver outputs: 40Hz for Gamma, 10Hz for Alpha.
• Neuro Duo 4 ($2,399) bundles both frequencies into one device — $1,199 cheaper than buying a Gamma 4 and an Alpha 4 separately, per Vielight’s own pricing.
• The Neuro Pro 2 ($5,000) is the only fully customizable unit, letting the user adjust frequency output rather than being locked to a single preset like the Alpha, Gamma, or Duo.
• Vielight announced a 228-subject pivotal clinical trial for Alzheimer’s disease in 2019. More than seven years on, the FDA still classifies Vielight’s Neuro devices as general wellness products — the same low-risk category that covers red light panels and masks — rather than a clearance tied to any specific disease.
• A rival pursuing the identical 40Hz gamma mechanism took the opposite path to market: Cognito Therapeutics’ Spectris AD holds FDA Breakthrough Device Designation and, per the company’s own 2026 announcement, completed enrollment of 670 patients in a randomized, sham-controlled pivotal trial (the HOPE Study) — Cognito has not yet brought a product to retail.

The full lineup at a glance

Buying a brain device and want it fast? A free 30-day Amazon Prime trial (sponsored) gets your red light panel in two days instead of waiting on a slower direct-from-brand order.

The 40Hz gamma question: two companies, two different paths to market

Vielight’s Neuro Gamma line is built around a specific, well-known piece of science: 40Hz gamma brain-wave entrainment, a mechanism that gained attention after MIT research suggested it could help clear amyloid plaque and support cognition in Alzheimer’s disease models. Vielight’s Neuro Gamma 4 and Neuro Duo 4 both deliver this 40Hz pulse via transcranial and intranasal near-infrared light, and the brand has been pursuing Alzheimer’s-specific research since at least 2019, when it announced a 228-subject pivotal clinical trial.

A separate company, Cognito Therapeutics, is chasing the same 40Hz gamma mechanism through a different route — synchronized light-and-sound stimulation rather than near-infrared light alone — and took a markedly different path to market. Cognito’s Spectris AD holds FDA Breakthrough Device Designation, and the company announced in 2026 that it had completed enrollment of 670 participants in the HOPE Study, a randomized, double-blind, sham-controlled pivotal trial spanning 70 U.S. sites, with topline results reported showing a measurable slowing of decline versus sham treatment. As of 2026, Cognito has not yet brought a cleared product to retail — it’s still working through the regulatory pathway.

Vielight’s Neuro devices, meanwhile, are available to buy today, classified by the FDA under the same “general wellness” category that covers ordinary red light panels — a low-risk designation that does not require proving effectiveness for any specific disease. That’s not a claim that Vielight’s devices don’t work; photobiomodulation research on gamma entrainment is real and ongoing. But it is a meaningfully different regulatory story than a device going through a sham-controlled pivotal trial before it reaches consumers. If the reason you’re considering a $1,799-$2,399 Neuro device is specifically for Alzheimer’s or dementia support, know that Vielight’s own devices have not completed the kind of trial Cognito is running, and are not FDA-cleared for that use.

Who should buy which Vielight device

• Buy the X-Plus 4 ($449) if nasal/systemic use is all you want — it’s already our top overall pick in the best nasal red light therapy guide, and costs a fraction of any Neuro device.
• Buy Neuro Gamma 4 or Neuro Alpha 4 ($1,799 each) if you only want one frequency — Gamma for a focus-oriented 40Hz session, Alpha for a relaxation-oriented 10Hz session.
• Buy Neuro Duo 4 ($2,399) if you want both frequencies — it saves $1,199 versus buying Gamma 4 and Alpha 4 separately.
• Think carefully before buying any Neuro device specifically for dementia or Alzheimer’s support — Vielight’s Neuro line carries no FDA clearance for that use, and the most rigorous sham-controlled trial on this exact 40Hz mechanism (Cognito Therapeutics’ HOPE Study) belongs to a different company’s different device, not to Vielight’s.
• Skip the $5,000 Neuro Pro 2 unless you specifically need adjustable frequency output — the preset Alpha, Gamma, and Duo units cover the same core 10Hz/40Hz territory at a third to half the price.

Vielight’s hardware claims — wavelengths, frequencies, and pricing — check out against its own live store, and the brand genuinely pioneered both intranasal photobiomodulation and consumer gamma-entrainment devices. But the highest-priced devices in its catalog are marketed around a disease connection the company’s own regulatory status doesn’t yet support, while a competitor working the same science is still mid-trial. Buy the Neuro line as a general wellness device, not as a dementia treatment.

Red light and near-infrared devices are general wellness products, not a treatment for any specific medical condition. “FDA general wellness” is a low-risk regulatory category, not a clearance confirming individual results, and nothing here is medical advice — talk to a qualified clinician before starting any light therapy regimen, especially for cognitive or neurological concerns. Prices and specs were verified against Vielight’s own live store and Cognito Therapeutics’ public trial announcements in September/October 2026 and change without notice.